Author’s response to reviews

Title: Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo

Authors:

Frank M Klenke (frank.klenke@dkf.unibe.ch)
Amir Abdollahi (a.amir@dkfz.de)
Elisabeth Bertl (elisabeth.bertl@gmx.net)
Martha-Maria Gebhard (gebhard@exchi.uni-heidelberg.de)
Volker Ewerbeck (volker.ewerbeck@ok.uni-heidelberg.de)
Peter E Huber (p.huber@dkfz.de)
Axel Sckell (axel.sckell@charite.de)

Version: 4 Date: 14 March 2007

Author’s response to reviews: see over
Berlin, March 14th, 2007

Manuscript: MS: 1315524864100251 - Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.

Dear Members of the BioMed Central Editorial Team,

Thank you very much for your last email from March 8th, 2007 confirming the acceptance of the manuscript of our above mentioned study pending on formatting changes.

The formatting changes requested have been performed as follows:

- Dr. Klenke's middle name now is given as an initial in the manuscript author list.
- The website address on page 5 in the chapter "Animal model and cell lines" was removed and replaced by the company's address "HTB-94, LGC Promochem GmbH, Wesel, Germany".

If there are any further questions, please do not hesitate to contact me again.

Yours sincerely

Dr. Axel Sckell
(Responsible and corresponding Author)